LYEL: Lyell Immunopharma, Inc. Stock

by  •  • Comments Off on LYEL: Lyell Immunopharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 118.11
Enterprise Value ($M) -2.21
Book Value ($M) 336.52
Book Value / Share 22.79
Price / Book 0.35
NCAV ($M) 215.90
NCAV / Share 14.62
Price / NCAV 0.55

Profitability (mra)
Return on Invested Capital (ROIC) -0.85
Return on Assets (ROA) -0.48
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 7.49
Current Ratio 7.49

Balance Sheet (mrq) ($M)
Current Assets 309.18
Assets 429.80
Liabilities 93.28
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.06
Operating Income -218.93
Net Income -342.99

Cash Flow Statement (mra) ($M)
Cash From Operations -162.39
Cash from Investing 122.42
Cash from Financing 1.33

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-15 13G/A Foresite Capital Fund IV, L.P. 9.20 39.44
02-14 13G/A ARCH Venture Fund IX, L.P. 13.10 0.33
02-05 13G/A BlackRock, Inc. 4.50 -7.25
11-12 13G/A Vanguard Group Inc 3.93 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2025-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-03 28,100 110,109 25.52
2025-06-02 117,223 379,115 30.92
2025-05-30 348,495 629,425 55.37
2025-05-29 250,841 485,876 51.63

(click for more detail)

Similar Companies
KYTX – Kyverna Therapeutics, Inc. LVTX – LAVA Therapeutics N.V.
LXRX – Lexicon Pharmaceuticals, Inc. MCRB – Seres Therapeutics, Inc.
MDGL – Madrigal Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io